全文获取类型
收费全文 | 23293篇 |
免费 | 1615篇 |
国内免费 | 130篇 |
专业分类
耳鼻咽喉 | 316篇 |
儿科学 | 638篇 |
妇产科学 | 387篇 |
基础医学 | 3086篇 |
口腔科学 | 512篇 |
临床医学 | 2104篇 |
内科学 | 4302篇 |
皮肤病学 | 314篇 |
神经病学 | 2677篇 |
特种医学 | 773篇 |
外国民族医学 | 1篇 |
外科学 | 3084篇 |
综合类 | 314篇 |
一般理论 | 14篇 |
预防医学 | 2206篇 |
眼科学 | 758篇 |
药学 | 2066篇 |
中国医学 | 62篇 |
肿瘤学 | 1424篇 |
出版年
2023年 | 99篇 |
2022年 | 148篇 |
2021年 | 408篇 |
2020年 | 233篇 |
2019年 | 372篇 |
2018年 | 474篇 |
2017年 | 374篇 |
2016年 | 385篇 |
2015年 | 432篇 |
2014年 | 640篇 |
2013年 | 1010篇 |
2012年 | 1435篇 |
2011年 | 1510篇 |
2010年 | 825篇 |
2009年 | 687篇 |
2008年 | 1372篇 |
2007年 | 1531篇 |
2006年 | 1474篇 |
2005年 | 1532篇 |
2004年 | 1442篇 |
2003年 | 1368篇 |
2002年 | 1355篇 |
2001年 | 298篇 |
2000年 | 291篇 |
1999年 | 334篇 |
1998年 | 302篇 |
1997年 | 275篇 |
1996年 | 228篇 |
1995年 | 254篇 |
1994年 | 166篇 |
1993年 | 207篇 |
1992年 | 222篇 |
1991年 | 193篇 |
1990年 | 166篇 |
1989年 | 180篇 |
1988年 | 156篇 |
1987年 | 172篇 |
1986年 | 156篇 |
1985年 | 174篇 |
1984年 | 161篇 |
1983年 | 164篇 |
1982年 | 201篇 |
1981年 | 205篇 |
1980年 | 172篇 |
1979年 | 121篇 |
1978年 | 114篇 |
1977年 | 139篇 |
1976年 | 126篇 |
1975年 | 91篇 |
1974年 | 71篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
2.
Tofacitinib is an immunosuppressive and disease-modifying therapy in rheumatoid arthritis. It may result in many infections flaring up. It is important to take precautions of all kinds (cardiovascular, malignancy, infections etc.) before starting tofacitinib. In this article, we have highlighted important steps where we need to take precautions before starting tofacitinib. 相似文献
3.
4.
5.
Jamaal L. Benjamin MD PhD Rebecca Dennis DO Stacy White Jr MD David Munson MD Sudha A. Anupindi MD Maciej Piskunowicz MD Kassa Darge MD PhD Ami Gokli MD Misun Hwang MD 《Journal of ultrasound in medicine》2020,39(5):1031-1036
Bowel diseases of prematurity, including necrotizing enterocolitis, are dreaded ailments of neonates. Early diagnosis is difficult, with clinical and radiographic findings often inconclusive. We present a novel use of contrast-enhanced ultrasound in detection of pediatric bowel disease. Early identification of compromised blood flow or an at-risk bowel can be quantitatively detected and monitored. This ability has implications for guidance of emerging therapies, allowing targeting of inflammation. These findings represent an advancement in detection of bowel disease in neonates. 相似文献
6.
Shylo R. Johnson Dennis Slate Kathleen M. Nelson Amy J. Davis Samual A. Mills John T. Forbes Kurt C. VerCauteren Amy T. Gilbert Richard B. Chipman 《Viruses》2021,13(2)
Since the 1990s, oral rabies vaccination (ORV) has been used successfully to halt the westward spread of the raccoon rabies virus (RV) variant from the eastern continental USA. Elimination of raccoon RV from the eastern USA has proven challenging across targeted raccoon (Procyon lotor) and striped skunk (Mephitis mephitis) populations impacted by raccoon RV. Field trial evaluations of the Ontario Rabies Vaccine Bait (ONRAB) were initiated to expand ORV products available to meet the rabies management goal of raccoon RV elimination. This study describes the continuation of a 2011 trial in West Virginia. Our objective was to evaluate raccoon and skunk response to ORV occurring in West Virginia for an additional two years (2012–2013) at 75 baits/km2 followed by three years (2014–2016) of evaluation at 300 baits/km2. We measured the change in rabies virus-neutralizing antibody (RVNA) seroprevalence in targeted wildlife populations by comparing levels pre- and post-ORV during each year of study. The increase in bait density from 75/km2 to 300/km2 corresponded to an increase in average post-ORV seroprevalence for raccoon and skunk populations. Raccoon population RVNA levels increased from 53% (300/565, 95% CI: 50–57%) to 82.0% (596/727, 95% CI: 79–85%) during this study, and skunk population RVNA levels increased from 11% (8/72, 95% CI: 6–20%) to 39% (51/130, 95% CI: 31–48%). The RVNA seroprevalence pre-ORV demonstrated an increasing trend across study years for both bait densities and species, indicating that multiple years of ORV may be necessary to achieve and maintain RVNA seroprevalence in target wildlife populations for the control and elimination of raccoon RV in the eastern USA. 相似文献
7.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献8.
9.
10.